Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharmacotherapy. 2000 Jun;20(6):653-6.

Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis.

Author information

  • 1Department of Pharmacy, Clarian Health Partners, Inc., Indiana University Hospital, Indianapolis, USA.

Abstract

STUDY OBJECTIVE:

To compare the performance of polyclonal fluorescence polarization immunoassay (pFPIA) with that of enzyme-multiplied immunoassay technique (EMIT) in patients receiving vancomycin and hemodialysis.

SETTING:

Outpatient hemodialysis center.

PATIENTS:

Seven subjects with end-stage renal disease treated with hemodialysis 3 times/week with a cellulose triacetate hemodialyzer.

INTERVENTION:

Subjects received vancomycin 1000 mg intradialytically during the first study session and 750 mg every other hemodialysis session thereafter for 4 weeks.

MEASUREMENTS AND MAIN RESULTS:

Blood samples were obtained throughout the study, and vancomycin serum concentrations were determined by pFPIA and EMIT. The mean +/- SD difference (estimate of bias) between assays was -1.10 +/- 1.35 mg/L. The limits of agreement (mean difference +/- 1.96 x SD) between them were -3.80-1.60 mg/L.

CONCLUSION:

Our data suggest that the manufacturer's changes in the vancomycin pFPIA eliminated overestimation of drug concentrations in patients undergoing high-permeability hemodialysis.

PMID:
10853620
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Write to the Help Desk